Freenome Raises $254 Million to Speed up Early Most cancers Detection Platform
What it is best to know:
– Freenome, a frontrunner in blood-based early most cancers detection, has raised $254 million in a brand new funding spherical fueled by its modern multiomics platform and promising suite of checks. The financing was led by Roche with participation from a16z Life Sciences Progress Fund, BrightEdge Ventures of the American Most cancers Society, ARK Investments, ArrowMark Companions, Artis Ventures, Bain Capital Life Sciences, Cormorant Capital, DCVC, Eventide Asset Administration LLC, Intermountain Ventures, Perceptive Advisors, Polaris Companions, Pura Vida Investments, Quest Diagnostics, RA Capital Administration, Sands Capital, Part 32, Squarepoint Capital.
– This funding will speed up the event and commercialization of checks for numerous cancers, doubtlessly saving lives via earlier detection.
Concentrate on lethal and actionable cancers
Early detection is essential for bettering most cancers outcomes and decreasing mortality charges. Freenome's multiomics platform analyzes numerous organic indicators within the blood to detect most cancers at an early stage. The corporate has two ongoing medical trials: PREEMPT CRC (colorectal most cancers) and PROACT LUNG (lung most cancers). Freenome can be growing checks to display for different cancers as a part of its multi-cancer analysis applications, together with the Vallania Examine. The Vallania Examine is a multicenter most cancers detection analysis program with greater than 6,200 members evaluating blood samples from each most cancers and non-cancer sufferers to grasp patterns related to lung most cancers and different precedence cancers.
“We’re grateful for the help and belief of our traders. Collectively, we share a dedication to assembly the pressing want for higher most cancers screening options as we try to make early most cancers detection simpler, extra accessible and extra actionable for everybody,” mentioned Mike Nolan, CEO of Freenome. “With this funding, we’re effectively positioned to comprehend the complete potential of our platform in delivering checks for early most cancers detection.”